Systemic Lupus Erythematosus Clinical Trial
Official title:
The Impact of Exercise on Hand Function, on Activities of Daily Living (ADLs) Performance and Quality of Life of Patients With Systemic Lupus Erythematosus (SLE)
A total of 240 consecutive SLE patients fulfilling the SLICC classification criteria was
evaluated. Sixty two patients who met the inclusion criteria were randomly assigned to the
exercise group (n=32) or the control group (n=30).
Patients in the exercise group performed a program of strengthening, stretching and
resistance upper limbs exercises, of 30 minutes duration daily, for 12 weeks. Performance of
daily activities was evaluated with the DASH and HAQ questionnaires, grip and pinch strength
with the Jamar dynamometer and pinch gauge tools respectively, dexterity with the Purdue
pegboard test and the quality of life with the LUPUSQoL questionnaire at 0, 6, 12 (end of the
exercise program) and 24 weeks for both groups. SLE activity and cumulative organ damage were
evaluated with the SLE disease activity index 2000 (SLEDAI-2K) and SLICC/ACR-DI,
respectively.
A total of 240 consecutive SLE patients fulfilling the SLICC classification criteria was
evaluated. Sixty two patients who met the inclusion criteria [age>18, upper limb arthralgias,
and DASH (Disabilities of the Arm, Shoulder, and Hand) questionnaire score>10)] were randomly
assigned to the exercise group (n=32) or the control group (n=30).
Patients in the exercise group performed a program of strengthening, stretching and
resistance upper limbs exercises, of 30 minutes duration daily, for 12 weeks. Performance of
daily activities was evaluated with the DASH and HAQ questionnaires, grip and pinch strength
with the Jamar dynamometer and pinch gauge tools respectively, dexterity with the Purdue
pegboard test and the quality of life with the LUPUSQoL questionnaire at 0, 6, 12 (end of the
exercise program) and 24 weeks for both groups. SLE activity and cumulative organ damage were
evaluated with the SLE disease activity index 2000 (SLEDAI-2K) and SLICC/ACR-DI,
respectively.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT03843125 -
A Study of Baricitinib in Participants With Systemic Lupus Erythematosus (SLE)
|
Phase 3 | |
| Recruiting |
NCT05698173 -
Systemic Lupus Erythematosus and Accelerated Aging
|
N/A | |
| Active, not recruiting |
NCT01649765 -
Pediatric Lupus Trial of Belimumab Plus Background Standard Therapy
|
Phase 2 | |
| Recruiting |
NCT05704153 -
Modelling and Control of Non-invasive Vagus Nerve Stimulation for Autoimmune Diseases (1A)
|
N/A | |
| Completed |
NCT05048238 -
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
|
Phase 1 | |
| Recruiting |
NCT06056778 -
The Prevalence Evaluation of Systemic Lupus Erythematosus in Russian Patients With Reproductive Issues (PRISMA)
|
||
| Completed |
NCT04358302 -
Individual Patient Exposure and Response in Pediatric Lupus
|
N/A | |
| Completed |
NCT02554019 -
Proof-of-Concept Study With BT063 in Subjects With Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT04835883 -
Exploring the Efficacy and Safety of CS20AT04 (Allogenic Bone Marrow-Derived Stem Cell) in Systemic Lupus Erythematosus Patients
|
Phase 2 | |
| Terminated |
NCT02665364 -
Phase IIb Study of IFN-K in Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT00278538 -
Cyclophosphamide and Rabbit Antithymocyte Globulin (rATG)/Rituximab in Patients With Systemic Lupus Erythematosus
|
Phase 2 | |
| Completed |
NCT00069342 -
Health Beliefs and Health Behaviors Among Minorities With Rheumatic Diseases
|
||
| Completed |
NCT03252587 -
An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus
|
Phase 2 | |
| Terminated |
NCT02066311 -
Nelfinavir in Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT01892748 -
Cholecalciferol Supplementation on Disease Activity, Fatigue and Bone Mass on Juvenile Systemic Lupus Erythematosus.
|
N/A | |
| Terminated |
NCT01689025 -
An Investigation of Safety and Tolerability of NNC0114-0006 in Subjects With Systemic Lupus Erythematosus (SLE)
|
Phase 1 | |
| Completed |
NCT01475149 -
Effect of HCQ on AnxA5 Resistance Assay in Antiphospholipid (aPL) Positive Patients With and Without Systemic Lupus Erythematosus (SLE)
|
N/A | |
| Unknown status |
NCT01712529 -
Physical Exercise, Endothelial Function and Progenitor Endothelial Cells in Systemic Lupus Erythematosus Patients
|
N/A | |
| Completed |
NCT00962832 -
A Study to Evaluate the Efficacy and Safety of Rontalizumab in Patients With Moderately to Severely Active Systemic Lupus Erythematosus
|
Phase 2 | |
| Recruiting |
NCT00747578 -
Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan
|
N/A |